Discover this podcast and so much more

Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

Defining and Measuring the Aging Process (Dr. Vadim Gladyshev)

Defining and Measuring the Aging Process (Dr. Vadim Gladyshev)

FromTranslating Aging


Defining and Measuring the Aging Process (Dr. Vadim Gladyshev)

FromTranslating Aging

ratings:
Length:
32 minutes
Released:
Jul 27, 2022
Format:
Podcast episode

Description

Joining Chris today is Dr. Vadim Gladyshev, Professor of Medicine at Harvard Medical School, Director of Redox Medicine at Brigham and Women's Hospital, and a member of the National Academy of Sciences. The Gladyshev lab studies redox biology and trace elements as they relate to cancer, reproduction, and aging. Today, Dr. Gladyshev shares with us how his research group investigates the aging process and how aging is quantified in academic research.
Dr. Gladyshev begins by discussing how he got involved in the longevity sector. He goes on to explain that aging has not been clearly defined, and how many researchers define aging differently. He contends that aging should be studied as opposed to age-related diseases because age-related diseases are influenced by other factors aside from aging. The interview concludes with the importance of conferences that address the science of longevity and how these events connect bright minds to tackle unsolved problems in the field.
Episode Highlights:
How Dr. Gladyshev got involved in aging
The relationship between selenium and longevity
How longevity is studied in the Gladyshev lab
What is rejuvenation?
The importance of measuring the aging process using clocks
Using experimental and computational methods to alter clocks
How the biotech industry quantifies aging
Targeting aging and not age-related diseases
The importance of conferences targeting longevity

Quotes:
“In general we try to address fundamental questions in the biology of aging — really trying to understand, ‘What is aging? How can we fundamentally adjust lifespan or target aging?’ … And we try to identify new areas of potential growth for the field.”
“We work on cross-species analysis to understand how the lifespan is shaped over evolutionary timescales and how we can utilize what we learn from evolution in targeting aging and lifespan.”
“Many changes can be measured as an organism moves from young to old. So this might be useful for measuring the progress of normal aging. But when you're intervening in aging, you don't want to reverse all of those changes, because some of those changes are evidence of the body's protective responses in action.”
“Just to play devil's advocate for a second: why would you want to target aging if you still got sick and died at the same rate?”
“Mortality is an integrative feature of not just the aging process, but interaction with the environment.”
Links:
Email questions, comments, and feedback to podcast@bioagelabs.com
Translating Aging on Twitter:https://twitter.com/BioAgePodcast ( @bioagepodcast)
BIOAGE Labs Websitehttps://bioagelabs.com/ ( BIOAGELabs.com)
BIOAGE Labs Twitterhttps://twitter.com/bioagelabs?lang=en ( @bioagelabs)
BIOAGE Labshttps://www.linkedin.com/company/bioage-labs/ ( LinkedIn)


https://www.linkedin.com/in/vadim-gladyshev-82268b153/ (Dr. Vadim’s Linkedin)
https://gladyshevlab.bwh.harvard.edu/ (Gladyshev lab Website)
https://mobile.twitter.com/gladyshev_lab (Gladyshev lab Twitter)
Released:
Jul 27, 2022
Format:
Podcast episode

Titles in the series (51)

On Translating Aging, we talk with the worldwide community of researchers, entrepreneurs, and investors who are moving longevity science from the lab to the clinic. We bring you a commanding view of the entire field, in the words of the people and companies who are moving it forward today. The podcast is sponsored by BioAge labs, a clinical-stage biotechnology company developing therapies to extend human healthspan by targeting the molecular causes of aging.